Ubiquigent and BMS now to partner on Drug Discovery

Science

Ubiquigent Limited have announced a change in partner from Celgene to BMS which will facilitate the latter getting the most out of the strength and breadth of Ubiquigent’s deubiquitylase enzyme inhibitor drug discovery platform and expertise. Ubiquigent has a strong track record in the development of DUB inhibitors by supporting the drug discovery work of its partners through access to its Drug Discovery Screening Platform and also access to its own developing portfolio of novel DUB inhibitors as part of Collaborative Drug Discovery partnerships where these novel DUB inhibitors may be licensed and further developed.

Mr. Jason Mundin, MD of Ubiquigent, said: "We are delighted to continue this partnership and look forward to supporting Bristol Myers Squibb in the development of novel DUB inhibitors for patients with unmet medical needs."

“We are delighted to continue this partnership and look forward to supporting Bristol Myers Squibb in the development of novel DUB inhibitors for patients with unmet medical needs“

Leigh Dilley ldilley@biostratamarketing.com

See all the latest jobs in Science
Return to news